Additionally, mutations in TP53 and enhanced HER2 activation or dimerization can contribute to HER2+ BC, with HER2 interacting with p53 upregulated modulator of apoptosis (PUMA) to promote cancer cell survival (Figure 1) [21,22,23]. This evidence concerns the gene ERBB2 and cancer.